BACKGROUND The long term outcome of drug related liver disease is unknown. AIMS To study the natural history of histologically proved drug induced hepatotoxicity. METHODS 110 patients with liver ...

Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...

The following is a summary of “Bucillamine-induced membranous nephropathy versus primary membranous nephropathy: comparing ...

A recent analysis shows that additional invasive staging modalities lead to relevant changes in target volume in some ...

Thymic epithelial tumors are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic ...

Perspective Therapeutics, Inc. (NYSE: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient ...

New data from the Phase II RAINFOL-01 study shows rinatabart sesutecan (Rina-S), an investigative antibody-drug conjugate, ...

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

Genmab (GMAB) announced updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan, an investigational folate ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.